RAVE-HD: A Novel Sequential Deep Learning Approach for Heart Disease Risk Prediction in e-Healthcare

RAVE-HD:一种用于电子医疗中心脏病风险预测的新型序列深度学习方法

阅读:1

Abstract

Background/Objectives: Heart disease (HD) is recently becoming the foremost cause of death worldwide, underlining the importance of early and correct diagnosis to improve patient outcomes. Although Internet of Things (IoT)-enabled machine learning approaches have demonstrated encouraging outcomes in screening, existing approaches often face challenges such as imbalanced dataset handling, influential feature selection identification, and the ability to adapt to evolving HD data forms. To tackle the aforementioned challenges, we present a sequential hybrid approach, RAVE-HD (ResNet And Vanilla RNN Ensemble for HD), that combines a number of cutting-edge techniques to enhance screening. Methods: Preprocessing phase includes duplicates removal and feature scaling for data consistency. Recursive Feature Elimination is employed to extract the most informative features, while a proximity-weighted random synthetic sampling technique addresses class imbalance to reduce class biases. The proposed RAVE model in RAVE-HD approach sequentially integrates a Residual Network (ResNet) for high-level feature extraction and Vanilla Recurrent Neural Network to capture the non-linearity of the feature relationships present in the HDHI medical dataset. Results: Compared to ResNet and Vanilla RNN baselines, the proposed RAVE model attained superior results: 92.06% accuracy and 97.12% ROC-AUC. Stratified 10-fold cross-validation validated the robustness of RAVE, while Sensitivity-to-Prevalence analysis demonstrated stable recall and predictable precision across varying disease prevalence levels. Additional evaluations, including bootstrap and DeLong analyses, showed statistical significance (p<0.001) of the discriminative gains of RAVE. Minimum Clinically Important Difference (MCID) evaluation confirmed clinically meaningful improvements (≥3%) over strong baselines. Cross-dataset validation using the CVD dataset verified robust generalization (92.4% accuracy). SHAP analysis provided interpretability to build clinical trust. Conclusions: RAVE-HD shows promise as a reliable, explainable, and scalable solution for large-scale HD screening, consistently performing well across diverse evaluations and datasets. Through statistical validation, the RAVE-HD approach emerges as a practical decision-support tool in HD predictive screening results.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。